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BACKGROUND Meningococcal C conjugate (MenC) vaccine was introduced as part of the Brazilian National Immunisation 
Program in 2010 for children < 1 year of age.
OBJECTIVES The study objective was to evaluate the impact of this vaccination strategy.
METHODS An observational, mixed ecological and analytical study was conducted, based on time series panel data from 
surveillance records (2001-2013).
FINDINGS A total of 37,538 of meningococcal disease cases were recorded during the study period. Of these, 19,997 were 
attributed to serogroup C. A decrease in meningococcal disease serogroup C (MDC) incidence among children aged < 1 year 
[65.2%; 95% confidence interval (CI): 20.5-84.7%] and 1-4 years (46.9%; 95%CI: 14.6-79.1%) were found in the three years 
following vaccination introduction. Vaccination impact on the reduction of MDC incidence varied from 83.7% (95%CI: 51.1-
100.0%) in the Midwest region to 56.7% (95%CI: 37.4-76.0%) in the Northeast region.
MAIN CONCLUSIONS Vaccination against MDC in Brazil had a positive impact on the population of children aged < 1 year, across all 
regions, and on the 1-4 year-old cohort. Nevertheless, in our view there is scope for improving the vaccination strategy adopted in Brazil.
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Meningococcal disease (MD) is endemic in Brazil and 
sporadic outbreaks have been recorded. Meningococcus 
is the leading cause of bacterial meningitis in Brazil (MS/
SVS 2014). Until 2005, serogroup B was the most frequent 
isolate in invasive MD cases (67%) across all age groups 
(PAHO 2007). Thereafter, circulation of serogroup C in-
creased, becoming the most predominant and accounting 
for over 74% of isolates in 2010 (Ibarz-Pavon et al. 2012).
The incidence of MD was very high, approximately 1.6 
cases per 100,000 population, with the highest incidence 
occurring among infants and young children (Sáfadi et al. 
2015), as well as recurring outbreaks in different regions 
(Gorla et al. 2012, Iser et al. 2012). This led to the inclu-
sion of meningococcal C conjugate (MenC) vaccine in the 
National Immunisation Programme in 2010 (SI-PNI/MS/
SVS 2010). The recommended regimen consisted of two 
doses (at three and five months of age) and one booster 
(between 12-15 months of age). Infants aged 12-23 months 
received one dose of the vaccine in the year of implemen-
tation of the program. Three Brazilian regions reached the 
target vaccination coverage (> 95%) in the first year fol-
lowing program implementation (2011). The Northeast re-
gion achieved this in 2013; the Northern region achieved a 
vaccination coverage ranging between 80% and 90% dur-
ing the study period (SI-PNI/MS/SVS 2010).
The incidence and serogroup circulation of MD var-
ies across the Brazilian regions. Serogroup C became 
predominant in the following regions: Southeast, since 
2002-2003; Midwest, since 2005-2006; Northeast, since 
2007-2008; Northern, since 2008-2009; and, more re-
cently, Southern since 2012 (de Moraes 2016).
Although some studies have evaluated the introduction 
of the vaccine in Brazilian municipalities (Cardoso et al. 
2012, Tauil et al. 2014), there are no reported studies as-
sessing the impact of this strategy on a national scale. The 
objective of this study was, therefore, to evaluate the impact 
of the vaccination program in Brazil on the MD incidence 
rate, according to the country’s geographical regions.
MATERIALS AND METHODS
Study type - This is an observational, mixed ecologi-
cal (aggregated in time and space) (Morgenstern 1995), 
analytical study, with time series analysis based on panel 
data (cross-sectional observations at different points in 
time) (Hsiao 2007).
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Data source - This study is based on the Notifiable 
Diseases Information System (Sinan) database that re-
cords all MD cases identified by the surveillance sys-
tem. MD notification is mandatory in Brazil.
The population databases used were the Live Birth In-
formation System (Sinasc) and the population estimates of 
the Brazilian Institute of Geography and Statistics (IBGE).
Study population and period - All confirmed MD 
cases occurring in Brazil between 2001 and 2013 and 
reported on the Sinan system were included in the study.
According to Surveillance Guideline (MS/SVS 2014), 
cases reported to Sinan are classified as meningococ-
cal meningitis, meningococcemia, or meningococcemia 
combined with meningococcal meningitis. The follow-
ing diagnostic criteria for MD case confirmation were 
used: culture, detection of bacterial DNA by polymerase 
chain reaction (PCR), antigen detection, clinical-epide-
miological criteria (case of close contact with a case con-
firmed by laboratory tests), gram-staining, and clinical 
criteria (with petechial or purpuric rash). Serogroup was 
determined only for MD cases confirmed by culture, 
PCR, antigen detection and clinical-epidemiological cri-
teria. Serogroup was classified as “unidentified” for MD 
cases confirmed by gram-staining and clinical criteria.
Unidentified serogroup MD cases were distributed 
according to the proportion of cases with identified se-
rogroups, taking into consideration region of residence, 
age group, and the trimester of symptom onset. The study 
population was composed of confirmed cases of MDC, 
in addition to “unidentified serogroup” cases, attributable 
to serogroup C, on the basis of proportional distribution.
All analyses were performed using the MDC inci-
dence, with and without unidentified serogroup case re-
distribution.
Study variables - Dependent variables: trimestral in-
cidence: MDC trimestral rates were calculated for each 
year of the study, by age group (< 1 year; 1-4 years; 5-9 
years; ≥ 10 years), and region of residence;
Independent variables: (i) year (historical trend): 
“year” variable for the period 2001-2013; (ii) trimesters 
(season): “month” variable (regardless of the year) was 
aggregated into trimesters: January-March (category = 
0, reference), April-June (category = 1), July-September 
(category = 2) and October-December (category = 3); 
(iii) vaccine (impact of vaccination): the time series was 
divided into periods, according to the stages of vaccina-
tion implementation, as follows: 2001-2009 = nº vacci-
nation program (pre-implementation, reference period = 
0); 2010 = implementation year (category = 1); 2011-2013 
= vaccination post-implementation period (category = 2). 
The latter was subdivided into the following categories: 
2 (year 2011), 3 (year 2012), and 4 (year 2013); (iv) region 
of residence: Northeast, Midwest, Southeast, South, and 
North; (v) age: < 1 year; 1-4 years; 5-9 years; ≥ 10 years.
Data analysis - The generalised least square (GLS) mod-
el with an autoregressive (AR) component equal to 1 was 
used to analyse the time series. The AR1 model included the 
temporal dependence of the data, taking into account that 
the rate in a given time t is influenced by the rate in t-1. This 
assumption seems plausible for MD trimester rate models.
Stages of model estimates were: (i) models separated 
by age group (< 1 year, 1-4 years, 5-9 years, and ≥ 10 years) 
across Brazil, using “year”, “trimester”, “region” and “vac-
cine” as explanatory variables (the latter having five cat-
egories), and using the outcome variable as MDC incidence 
at a specific age; (ii) models were estimated for each of the 
country’s regions and to ensure statistical power, the “vac-
cine” variable, with the three categories defined above (0, 1 
and 2), was used; (iii) diagnostic of regression models was 
performed (details are presented below); (iv) models were 
repeated using MDC incidence (outcome) without uniden-
tified serogroup case redistribution.
The statistical significance level was set at 5% (type 
I error) in regression models.
Residual diagnostics of the GLS statistical regres-
sion models were performed to evaluate homogeneity 
of variance between the panels; autocorrelation between 
the panels; and linearity, independence, and normality 
assumptions. The Shapiro-Wilk W-test for normal data 
was performed to assess the normality assumption of the 
residuals, and the data distribution was evaluated using 
the Quantile-Quantile plot and the Kernel density plot. 
To clarify the linearity assumption, distribution plots of 
the residuals (estimated values versus residuals) were 
evaluated. The study also evaluated whether residuals 
were free from serial autocorrelation (white-noise) using 
Q (Sperling & Baum 2001) and B (Bartlett 1955) statis-
tics. Finally, the Akaike information criterion (AIC) and 
Bayesian information criterion (BIC) values were as-
sessed, with and without panel standard error heterosce-
dasticity (Akaike 1974, Schwarz 1978). Based on these 
results, the decision was taken to adopt the model with 
the best fit (the model with the lowest AIC and BIC). 
Whenever the model did not fit GLS assumptions, a note 
of caution was included in the results.
In order to evaluate the estimated impact of MenC 
vaccination on the population, the number of expected 
MDC cases with and without MenC vaccine intervention 
was predicted, using the regression models, for the period 
2011-2013, both for Brazil and for each region. The impact 
was calculated as follows: Impact = (Ev - E)*100/E; where 
Ev = effect with vaccination for a given year, and E = ef-
fect without vaccination for the same year.
Analysis was performed using Microsoft Office Ex-
cel 2010 and STATA version 10.
Ethical aspects - This study was approved by the 
University of Brasília Faculty of Medicine Research 
Ethics Committee, Report No.908.096. The study used 
only non-nominal secondary data.
RESULTS
A total of 37,538 MD cases were recorded in the 
Sinan database between 2001 and 2013. Among 16,600 
(44.2%) confirmed MD cases, serogroup was known 
and distributed as follows: serogroup C, 9,503 (57.3%) 
cases; serogroup B, 5,999 (36.1%) cases; and other sero-
groups, 1,098 (6.6%) cases. In 20,938 (55.8%) MD con-
firmed cases serogroup was unknown. These uniden-
tified serogroup cases were redistributed according to 
identified serogroups, by region of residence, age group, 
and trimester of symptom onset. Therefore, a total of 
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10,494 (50.1%) MD cases were attributed to serogroup 
C. Finally, a total of 19,997 (the sum of 9,503 and 10,494) 
patients with MDC were included in this study (Fig. 1).
Seasonal variation in the trimester incidence of MDC 
cases with (n = 19,997) and without (n = 9,503) redistribu-
tion of unknown serogroup was almost identical (Fig. 2).
Total MDC incidence between 2001 and 2009 (pe-
riod before vaccine implementation) increased by ap-
proximately 100%, from 0.53 cases per 100,000 popu-
lation in 2001 to 1.09 cases per 100,000 population in 
2009. This increase occurred across all age groups and 
specifically, there was a 120% increase in the < 1 year 
age group (from 3.98 cases per 100,000 population in 
2001 to 8.78 cases per 100,000 population in 2009) and a 
72% increase in the 1-4 years age group (from 2.26 cases 
per 100,000 population in 2001 versus to 3.89 cases per 
100,000 population in 2009) (Table I).
MDC incidence increased in all geographical regions 
between 2001 and 2009. The highest increase occurred in 
the Northeast region (162%) (Table I). The Northern re-
gion was not included in this analysis because of the large 
number of trimesters with no cases or with all MD noti-
fied cases classified as unknown serogroup. The pattern 
in this region did not allow the redistribution of unknown 
serogroup MD cases for most of the study trimesters.
There was a historical trend of increased MDC across 
all age groups over the period 2001-2013, after control-
ling for seasonal trend and vaccine implementation (Table 
II). There were some exceptions: the Southeast region (1-4 
years age group) and the Southern region (1-4 years, 5-9 
years and > 10 years age groups). The model estimated an 
average annual increase of 0.14 cases per 100,000/trimes-
ter/year for the < 1 age group. This increase was greater in 
the Midwest and Southeast regions.
A statistically significant increase in MDC was 
found in the months of July and September in all age 
groups across Brazil, after controlling for historical 
trends and vaccine implementation (Table II).
The effect of vaccination on the average trimestral 
MDC incidence was adjusted according to historical 
trends, seasonal trends, and geographical regions. In 
the years following vaccine implementation (2011, 2012, 
and 2013), increasing gradients in the reduction of the 
incidence rates were observed across all age groups. 
Conversely, the vaccination effect decreased with age of 
the study population (Table II, Fig. 3).
A decrease in mean MDC incidence was found in 
subjects aged < 1 year after the introduction of the MenC 
vaccine, as follows: -1.13 cases/100,000/trimester/year 
in 2011, -1.58 in 2012, and -1.49 in 2013 (p < 0.001). A 
decrease in mean MDC incidence was also found in the 
1-4 years age group: -0.27 cases/100,000/trimester/year in 
2011, -0.64 in 2012, and -0.84 in 2013 (p < 0.001). In the 
5-9 years and ≥ 10 years age groups a decrease in MDC 
incidence was observed only in 2013: -0.22 cases/100,000/
trimester/year (p < 0.001) and -0.04 cases/100,000/trimes-
ter/year (p = 0.024), respectively (Table II, Fig. 3).
The four regions analysed showed a statistically sig-
nificant MDC incidence reduction in the < 1 year and 
1-4 years age groups (not including the Southern region). 
The largest impact was found in the Southeast and Mid-
west regions: -3.08 and -2.33 cases/100,000/trimester/
year, respectively, in the < 1 year group, and -0.86 and 
-0.82 cases/100,000/trimester/year, respectively, in the Fig. 1: description of meningococcal disease confirmed cases classi-
fied by serogroup (Brazil, 2001-2013).
Fig. 2: meningococcal disease incidence with and without serogroup C redistribution per trimester and year of symptom onset (Brazil, 2001-2013).
Impact of MenC vaccine in Brazil • Camile de Moraes et al.240
1-4 years age group. Smaller reductions were observed 
in the Northeast and Southern regions: -0.82 and -0.96 
cases/100,000/trimester/year, respectively, in the < 1 
year group, and -0.20 and -0.24 cases/100,000/trimester/
year, respectively, in the 1-4 years age group (Table II).
Estimates using the same time series models but con-
sidering MDC incidence without the redistribution of 
unidentified serogroup cases produced almost identical 
results. However, they systematically underestimated 
the coefficient.
Table III shows the results of the impact of MenC vac-
cination in terms of percentage reduction in MDC cas-
es, as derived from the regression models. For children 
aged < 1 and 1-4 years old, the reduction in the number 
of cases in Brazil, over the period 2011-2013, was 65.7% 
and 51.8%, respectively. The reduction, per region, among 
children aged < 1 year was highest in the Midwest region, 
and smallest in the Northeast region (Table III).
DISCUSSION
This was the first study to evaluate the impact of the 
introduction of MenC vaccination in Brazil, taking into ac-
count national data as well as regional and age differentials.
The estimation of vaccination impact included ad-
justments for time and seasonal trends, as a failure to 
take these into account could have affected the validity 
of the vaccination impact estimates. Overall, there was a 
historical trend of increased MDC across all age groups 
over the period 2001-2013, particularly in the Midwest 
and Southeast regions. The study estimated that the 
mean increase was 0.14 cases/100,000/trimester/year in 
the < 1 year age group. These findings reflect the ap-
TABLE I
Serogroup C meningococcal disease incidence by age group and region of residence (Brazil, 2001-2013)
Region
Age group  
(years)
Meningococcal disease serogroup C incidence (cases/100,000)
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011* 2012* 2013*
< 1 3.98 2.84 4.67 6.24 6.19 7.71 6.92 7.09 8.78 9.50 4.15 2.82 3.03
1-4 2.26 1.85 2.18 2.77 2.96 3.13 2.78 3.40 3.89 3.68 3.16 1.70 0.89
Brazil 5-9 0.95 1.06 0.90 1.50 1.41 1.61 1.61 1.71 2.00 2.03 1.87 2.05 1.42
≥ 10 0.23 0.25 0.26 0.37 0.36 0.38 0.43 0.54 0.62 0.71 0.70 0.71 0.58
Total 0.53 0.50 0.54 0.76 0.75 0.81 0.81 0.95 1.09 1.15 1.01 0.91 0.70
< 1 - - - 0.49 1.59 - - 1.86 - 1.63 - 1.30 1.60
1-4 0.48 0.68 0.27 0.33 0.20 1.21 0.54 - 0.92 0.48 0.70 0.42 0.22
North 5-9 0.18 0.70 0.69 1.16 - 0.23 1.06 0.22 0.56 - 0.22 0.42 0.22
≥ 10 0.32 0.22 0.17 0.35 0.03 0.20 0.27 0.38 0.47 0.29 0.20 0.29 0.39
 Total 0.31 0.33 0.24 0.45 0.07 0.30 0.38 0.35 0.51 0.30 0.24 0.30 0.38
< 1 0.00 0.26 1.69 1.47 2.09 3.14 2.37 2.62 4.90 3.11 2.64 1.32 2.55
1-4 0.93 0.41 0.52 0.57 0.93 0.58 0.90 1.18 1.95 0.91 1.09 0.94 0.50
Northeast 5-9 0.63 0.80 0.41 0.32 0.68 0.71 0.87 0.64 1.45 1.06 1.01 1.19 0.53
≥ 10 0.17 0.22 0.11 0.22 0.25 0.26 0.28 0.35 0.48 0.61 0.50 0.58 0.41
Total 0.29 0.30 0.20 0.28 0.38 0.38 0.42 0.48 0.76 0.71 0.62 0.67 0.46
< 1 4.40 0.00 3.02 4.88 5.66 7.22 8.05 7.64 9.08 4.53 2.65 2.39 1.49
1-4 1.51 1.62 0.33 0.72 2.64 3.53 2.81 3.30 3.63 3.62 2.13 0.81 0.66
Midwest 5-9 0.42 0.20 0.37 0.74 0.18 0.55 0.98 0.59 1.38 1.21 1.10 0.88 0.41
≥ 10 0.20 0.12 0.17 0.21 0.18 0.35 0.31 0.41 0.46 0.59 0.45 0.39 0.44
Total 0.41 0.25 0.26 0.38 0.46 0.72 0.67 0.74 0.89 0.90 0.65 0.48 0.47
< 1 8.48 6.59 9.17 12.10 11.06 14.93 13.72 12.86 15.65 18.97 7.62 5.16 4.19
1-4 4.25 3.59 4.60 5.87 5.83 6.17 5.32 6.97 7.27 7.90 6.41 3.38 1.64
Southeast 5-9 1.75 1.85 1.56 2.75 2.86 2.75 2.79 3.48 3.56 3.96 3.61 4.10 3.09
≥ 10 0.26 0.34 0.41 0.57 0.54 0.56 0.67 0.82 0.92 1.05 1.13 1.10 0.88
Total 0.81 0.80 0.94 1.29 1.25 1.32 1.33 1.59 1.71 1.92 1.70 1.51 1.13
< 1 2.24 1.51 2.77 5.00 5.26 3.42 2.05 4.55 4.20 4.85 1.32 0.44 2.79
1-4 1.40 1.22 1.55 2.14 1.96 1.93 1.90 1.43 1.53 1.11 1.56 0.35 0.41
South 5-9 0.29 0.12 0.60 1.24 0.60 1.99 0.62 0.83 0.23 0.83 0.69 0.47 0.26
≥ 10 0.20 0.14 0.18 0.16 0.25 0.19 0.17 0.22 0.19 0.19 0.19 0.17 0.18
Total 0.32 0.24 0.35 0.46 0.47 0.50 0.34 0.40 0.32 0.35 0.32 0.20 0.23
*: years in bold indicate period pos-vaccine implementation.
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TABLE III
Percentage case reduction estimated by the regression model for children aged < 1 year and children aged  
1-4 years in Brazil and regions in the years following the introduction of meningococcal C vaccination
Brazil
< 1 year 1-4 years
Variation in MDC cases (%) CI 95% Variation in MDC cases (%) CI 95%
2010 1.5 (119.6, 22.5) -4.2 (-23.2, 14.8)
2011 -54.6 (-75.3, -33.8) -21.8 (-40.8, -2.8)
2012 -70.9 (-91.7, -50.2) -57.6 (-76.8, -38.4)
2013 -70.7 (-91.6, -49.8) -74.5 (-92.7, -56.2)
2011-2013 -65.7 (-86.5, -44.9) -51.8 (-70.6, -33.0)
Northeast
2010 -28.2 (-52.5, -3.9) -44.8 (-90.9, 1.2)
2011-2013 -56.7 (-76.0, -37.4) -55.0 (-97.2, -12.9)
Midwest
2010 -55.0 (-97.0, -13.1) -9.4 (-46.5, 27.8)
2011-2013 -83.7 (-100.0, -51.1) -73.4 (-100.0, -39.1)
Southeast
2010 13.5 (-2.7, 29.7) 4.5 (-6.8, 15.8)
2011-2013 -65.4 (-82.2, -12.2) -42.9 (-72.3, -13.5)
South
2010 4.2 (-34.7, 43.0) -32.6 (-75.5, 10.3)
2011-2013 -60.1 (-91.7, -28.5) -44.0 (-88.4, 0.4)
CI: confidence interval; MDC: meningococcal disease serogroup C.
Fig. 3: average reduction of serogroup C meningococcal disease incidence * by age group after vaccine implementation (Brazil, 2010-2013); 
*: average reductions were estimated based on generalised least square (GLS) regression models considering as dependent variable the tri-
mester incidence rates for each year, and adjusted by historical trend and seasonality.
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pearance of a serogroup C strain belonging to a hyper-
virulent lineage (ST-103), first described in São Paulo, 
in the Southeast region in the early 2000s (Lemos et al. 
2007). This strain subsequently spread to other regions 
(Cardoso et al. 2012, Tauil et al. 2014). Furthermore, a 
seasonal predominance of the disease was observed in 
the winter months, from July to September. This is a 
known characteristic of MD in Brazil and also occurs in 
other countries (Halperin et al. 2012).
The MDC incidence reduction in Brazil was consis-
tent with MenC vaccination implementation. A signifi-
cant reduction in the number of estimated cases follow-
ing the introduction of the vaccination program (2011, 
2012 and 2013) was observed in children aged < 1 year 
and 1-4 years. A statistically significant decrease in the 
MDC incidence after the introduction of the vaccination 
program was also found in the 5-9 years and ≥ 10 years 
age groups in 2013, although the limited effects should be 
interpreted with caution. Furthermore, this study identi-
fied geographical region as a MenC vaccine impact modi-
fying variable in Brazil. Earlier and greater impacts were 
found in the Midwest region and in the Southeast region.
The MDC reduction in Brazil in children aged < 1 year 
between 2011 and 2013 [65.7%; 95% confidence interval 
(CI): 44.9-86.5%] shows the effect (direct and indirect) of 
vaccination on the target population. In the United King-
dom and in Spain, disease incidence in children aged < 1 
year following MenC vaccination decrease by 77.5% and 
85%, respectively (Balmer et al. 2002, Larrauri et al. 2005).
The reduction in estimated cases of MDC in children 
aged 1-4 years across Brazil, due to the implementation of 
vaccination program, was 51.8% (95%CI: 33.0-70.6%). This 
was smaller than the reduction estimated for children in the 
< 1 year age group and can be explained by the fact that this 
group includes children who may not have been vaccinated. 
The MDC incidence reduction attributed to vaccination in 
the 1-4 year age group in other countries was approximate-
ly 85% (Balmer et al. 2002, Larrauri et al. 2005).
The limited impact during 2013 in children aged 
5-9 years (p < 0.001) and ≥ 10 years (p = 0.024) may 
be a consequence of shifts in the cohort of vaccinated 
children over time, and particularly among children 
aged 5-6 years. The hypothesis of MD cyclical trends, 
dependent on natural immunity, and the occurrence of 
herd immunity should also be addressed. It is not clear 
whether younger vaccinating children will have an im-
pact, albeit low, on meningococcal carriage and whether 
this will have any indirect impact on disease incidence 
among older children. It is important to note that the 
prevalence of meningococcal carriage described in a 
meta-analysis study (Christensen et al. 2010) was found 
to be higher in adolescence and early adulthood (peak of 
23.7% at 19 years of age) than in childhood (4.5% among 
infants and 7.7% among 10-year-old subjects). Studies 
assessing these hypotheses are required.
Overall, the results of this study were comparable 
to those described in the literature (Balmer et al. 2002, 
Larrauri et al. 2005, Bettinger et al. 2009). The small 
differences between countries in the estimated impact 
of vaccination strategies can be justified, at least in part, 
by the methodology used for analysis, the specificities of 
disease epidemiology, and differences in vaccine imple-
mentation in each country. It is important to highlight 
that the impact estimate is derived from an ecological 
study, in which children in the pre-vaccination period 
were compared with children in the post-vaccination 
period; however, children in the post-vaccination period 
may or may not have been vaccinated, may have been 
vaccinated according to different vaccination schedules, 
or may have received different vaccine doses. Moreover, 
the model chosen for estimating the impact of vaccina-
tion was an adjusted time series; therefore, estimated 
impact parameters will be more conservative than those 
obtained using unadjusted analysis.
With regards to the age groups targeted by vaccina-
tion programs, the objective in Brazil was to directly im-
munise children aged < 2 years, specifically unweaned 
infants, as this age group has the highest at risk of me-
ningococcal disease in the country. Unlike other coun-
tries, in Brazil the incidence of MD does not peak among 
adolescents and young adults. This only occurs during 
outbreaks when high rates are found among adolescents 
and adults (Cardoso et al. 2012, Gorla et al. 2012, Iser et 
al. 2012). Almost all countries (Trotter et al. 2004, Trot-
ter & Ramsay 2007, Bettinger et al. 2009) implementing 
MenC vaccination in their immunisation programmes 
have opted to introduce catch-up campaigns for adoles-
cents, and these appear to have been crucial for generat-
ing high levels of herd immunity (Ramsay et al. 2003, 
Kinlin et al. 2009). Conjugate vaccines have the abil-
ity to reduce the prevalence of meningococcal carriage, 
resulting in a reduced risk of the disease, even among 
individuals who have not been vaccinated (Maiden et al. 
2008, Campbell et al. 2010). On the basis of this study’s 
data, it was not possible to find a relevant MDC reduction 
in other age groups not targeted by vaccination follow-
ing the introduction of the program. An example of this 
is no reduction in MDC cases among children aged < 3 
months after the introduction of vaccination programs in 
Brazil (de Moraes 2016). In the United Kingdom, there 
was a reduction in the total number of serogroup C cases 
in children < 3 months, attributed to an indirect protec-
tive effect of the vaccine (Campbell et al. 2009). These 
findings should be considered when evaluating the in-
clusion of other age groups for vaccination in Brazil.
Important sub-national variations, taking into account 
the regional analysis of the MenC vaccination impact, are 
described. Brazil is country with important variations in 
the implementation of health policies, such as immunisa-
tion programs, as a consequence of regional development 
and a decentralised health system. Ignoring this diversity 
may lead to misleading results. The sub-national analysis 
was useful to formulate hypotheses that may explain the 
lower than anticipated vaccine impact in some Brazilian 
regions. These hypotheses may address differentials re-
lated to vaccine coverage, quality of the disease surveil-
lance, as well as disease burden influenced by population 
density and presence of urban clusters.
Some of the study results (increasing impact of vac-
cination over time and regional variations in vaccination 
impact) may be explained, at least in part, by variations 
in the vaccination coverage and disease burden. MenC 
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vaccination implementation in Brazil took place be-
tween March and November 2010, and high coverage 
was achieved in the months following implementation in 
almost all the country’s regions. The only exception was 
the Northeast region, where the target recommended by 
the PIN-MS (95% coverage) was only reached in 2013 
(SI-PNI/MS). This may explain the low impact of the 
intervention in this region. The Southeast region con-
sistently had the highest MDC incidence, both prior to 
and following the introduction of the vaccination pro-
gram. Furthermore, there was a strong trend of increas-
ing MDC incidence, in the Southeast region, as well as 
in the Midwest region, in the period before the vaccina-
tion implementation. This may have influenced the high 
impact of the implementation of vaccination in these re-
gions. The limited median impact found in the Southern 
region may be related to the low MDC incidence and the 
late increase in serogroup C circulation between 2012 
and 2013, which are specific to these regions.
The results of the study must be interpreted with cau-
tion, taking into account a number of limitations. First, this 
study used secondary data sources; therefore, the possibil-
ity of underreporting and inconsistency in recording the 
variables of interest and case classification should be con-
sidered. Nevertheless, studies have shown that the Sinan 
system data is valid in the context of changes in the his-
torical trends of the disease (Azevedo et al. 2013). Secondly, 
the database used in this study contained a high percentage 
of MD cases with unidentified serogroups. This limitation 
was minimised by the proportional redistribution of these 
cases to achieve the same distribution as the laboratory 
confirmed cases, by region of residence, age group, and 
trimester of symptom onset (Miller et al. 2002). Serogroup 
identification improved over the study period; if the cases 
of unidentified serogroup had not been redistributed and 
had been excluded from the analysis, this may have resulted 
in a significant underestimation of the incidence, increased 
random error in the estimates (and the range of the confi-
dence intervals), and selection bias. A further limitation is 
the GLS regression assumptions. Violation of linearity and 
independence assumptions were identified in few analyses 
and their results must be considered with caution. Finally, 
the fact that this is an ecological study limits the general-
isability of results, for example, these findings cannot be 
compared with those of individual-based studies.
In conclusion, vaccination against MDC in Brazil is 
likely to have an impact on the target population (chil-
dren aged < 1 year) for all analysed regions, to a variable 
extent, and on the 1-4-year- old cohort. Nevertheless, it 
is our view that there is scope for improving the vac-
cination strategy adopted in Brazil. Vaccinating other 
age groups, for example adolescents, may increase the 
MenC vaccination impact, including a possible indirect 
effect on non-vaccinated groups. Moreover, our study 
results highlight the need to develop investigations to 
improve our understanding of how regional differences 
affect vaccine impact. Furthermore, monitoring vaccine 
coverage and further development of the MD surveil-
lance system are fundamental to improve vaccine im-
pact and to decrease the disease burden in Brazil.
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